You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Cardioprevention, CV Risk Reduction, and Cardiometabolic Updates

  • Authors: Deepak Bhatt, MD, MPH; Pamela B. Morris, MD; Martha Gulati, MD; Pam R. Taub, MD; Seth J. Baum, MD; George L. Bakris, MD; Karol Watson, MD, PhD; Sheldon E. Litwin, MD; Robert H. Eckel, MD
  • CME / ABIM MOC / CE Released: 12/30/2022
  • Valid for credit through: 12/30/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 2.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 2.50 ABIM MOC points

    Nurses - 2.50 ANCC Contact Hour(s) (1.25 contact hours are in the area of pharmacology)

    IPCE: 2.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for cardiologists, diabetologists and endocrinologists, primary care physicians (PCPs), nephrologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and any other healthcare practitioners (HCPs) involved in the care of patients at risk for cardiovascular (CV) events.

The goal of this activity is for the learner to be better able to discuss strategies to reduce the risk of CV events.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Current and emerging therapeutic approaches to manage dyslipidemia and decrease CV risk
    • Updates and advances in cardioprevention strategies for at-risk patients
    • Physiology and clinical importance of the interconnection between T2D, CVD, CKD, and/or obesity
    • Latest data supporting strategies to benefit patients with CVD, T2D, CKD, and/or obesity in complicated patients
  • Have greater competence related to
    • Application of clinical evidence and guidelines to select appropriate cardioprevention strategies to decrease CV risk and optimize outcomes in individual patients
    • Application of strategies for effective management of comorbidities in patients with T2D, CVD, CKD, and/or obesity to reduce CV risk and improve outcomes
  • Demonstrate greater confidence in their ability to
    • Implement interprofessional-based care in the management of patients with CVD


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Co-Chairs

  • Deepak Bhatt, MD, MPH

    Director of Mount Sinai Heart
    Dr Valentin Fuster Professor of Cardiovascular Medicine
    New York, New York

    Disclosures

    Deepak Bhatt, MD, MPH, has the following relevant financial relationships: 
    Research funding from:  89bio, Inc.; Abbott; Afimmune Limited; Aker BioMarine; Amarin Corporation plc; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer; Beren Therapeutics P.B.C.; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol Myers Squibb Company; Cardax, Inc.; CellProthera; Cereno Scientific; Chiesi; CSL Behring; Eisai, Inc.; Ethicon; Faraday Pharmaceuticals, Inc.; Ferring Pharmaceuticals; Forest Laboratories, Inc.; Fractyl Laboratories, Inc.; Garmin; HLS Therapeutics, Inc.; Idorsia Pharmaceuticals, Inc.; Ironwood Pharmaceuticals, Inc.; Ischemix, Inc.; Janssen; Javelin Biotech, Inc.; Lexicon Pharmaceuticals, Inc.; Lilly; Medtronic, Inc.; Moderna, Inc.; MyoKardia; NirvaMed, Inc.; Novartis; Novo Nordisk; Owkin, Inc.; Pfizer, Inc.; PhaseBio Pharmaceuticals, Inc.; PLx Pharma Inc.; Recardio Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Stasys Medical Corporation; Synaptic Pharmaceutical Corporation; The Medicines Company 

  • Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

    Professor of Medicine, Cardiology​
    Director, Seinsheimer Cardiovascular Health Program​
    The Medical University of South Carolina​
    Charleston, South Carolina

    Disclosures

    Pamela B. Morris, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Amgen, Inc.; Esperion Therapeutics, Inc. 
    Contracted researcher for: Esperion Therapeutics, Inc. 

Speakers

  • Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

    Professor of Medicine
    Director, Preventive Cardiology
    Associate Director, Barbra Streisand Women's Heart Center
    Anita D. Friedman Chair in Cardiovascular Medicine & Research
    Smidt Heart Institute at Cedars Sinai Medical Center
    Los Angeles, California

    Disclosures

    Martha Gulati, MD, has no relevant financial relationships.

  • Pam R. Taub, MD, FACC, FASPC

    Professor of Medicine​
    University of California San Diego Health System
    Director​
    Step Family Foundation Cardiovascular Rehabilitation and Wellness Center​
    La Jolla, California

    Disclosures

    Pam R. Taub, MD, has the following relevant financial relationships: Amgen, Inc.; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Medtronic, Inc.; Novartis; Novo Nordisk; Sanofi 

  • Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC

    Chief Scientific Officer, Flourish Research​
    Clinical Affiliate Professor of Cardiology
    Department of Integrated Medical Science
    Charles E. Schmidt College of Medicine
    Florida Atlantic University
    Founder/President
    Excel Medical Clinical Trials
    Past President,
    American Society for Preventive Cardiology
    Boca Raton, Florida

    Disclosures

    Seth J. Baum, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Altimmune, Inc.; Amgen, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Esperion Therapeutics, Inc.; Lilly; Madrigal Pharmaceuticals, Inc.; Novartis; Regeneron Pharmaceuticals, Inc. 
    Speaker or member of speakers bureau for: Amgen, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Esperion Therapeutics, Inc.; Lilly; Regeneron Pharmaceuticals, Inc. 
    Research funding from:  Altimmune, Inc.; Amgen, Inc.; Ionis Pharmaceuticals; Lilly; Madrigal Pharmaceuticals, Inc.; NewAmsterdam Pharma; Novartis; Novo Nordisk; Regeneron Pharmaceuticals, Inc. 

  • George L. Bakris, MD

    Professor of Medicine​​
    Director​
    American Heart Association​
    Comprehensive Hypertension Center​​
    University of Chicago Medicine​
    Chicago, Illinois

    Disclosures

    George L. Bakris, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Alnylam Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Bayer; DiaMedica Therapeutics, Inc.; Horizon Pharma; Ionis Pharmaceuticals; KBP Biosciences Co., Ltd.; Merck; Novo Nordisk; Quantum Genomics 
    Research funding from: Bayer 

  • Karol Watson, MD, PhD, FACC

    Professor of Medicine/Cardiology​
    Co-Director, UCLA Program in Preventive Cardiology
    Director, UCLA Barbra Streisand Women's Heart Health Program
    David Geffen School of Medicine at UCLA
    Los Angeles, California

    Disclosures

    Karol Watson, MD, PhD, has the following relevant financial relationships: 
    Consultant or advisor for: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis 
    Speaker or member of speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc. 

  • Sheldon E. Litwin, MD

    Alicia Spaulding-Paolozzi Professor of Cardiology
    Medical Director, Echocardiography Laboratory
    Medical University of South Carolina
    Charleston, South Carolina

    Disclosures

    Sheldon E. Litwin, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Alleviant Medical; AXON; Occlutech; Rivus Pharmaceuticals, Inc. 
    Research funding from: AXON; Corvia Medical, Inc.; Lilly; V-Wave Inc. 

  • Robert H. Eckel, MD, FAHA, FACC

    Professor of Medicine, Emeritus​
    Division of Endocrinology, Metabolism, and Diabetes​
    Division of Cardiology​
    Charles A. Boettcher II Chair in Atherosclerosis, Emeritus​​
    Denver, Colorado

    Disclosures

    Robert H. Eckel, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Amarin Corporation plc; Amgen, Inc.; Arrowhead Pharmaceuticals, Inc.; Lexicon Pharmaceuticals, Inc.; The Healthy Aging Company 

Editor

  • George Boutsalis, PhD

    Senior Director, Content Development, Medscape, LLC

    Disclosures

    George Boutsalis, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 2.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 2.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Cardioprevention, CV Risk Reduction, and Cardiometabolic Updates

Authors: Deepak Bhatt, MD, MPH; Pamela B. Morris, MD; Martha Gulati, MD; Pam R. Taub, MD; Seth J. Baum, MD; George L. Bakris, MD; Karol Watson, MD, PhD; Sheldon E. Litwin, MD; Robert H. Eckel, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/30/2022

Valid for credit through: 12/30/2023, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Case Discussions in Lipid Management for ASCVD Risk Reduction


Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

New Chest Pain Guidelines: Highlights for Your Practice


Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Exploring New Targets for CV Risk Reduction


Pam R. Taub, MD, FACC, FASPC

Rare Lipid Disorders: Spotlight on HoFH


Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC

Antiplatelet and Antithrombotic Insights for Primary and Secondary Prevention: Where Are We in 2022?


Deepak L. Bhatt, MD, MPH, FACC, FAHA, MSCAI, FESC

Addressing the Undertreatment of Hypertension: Who, What, How, Why, and When?


George L. Bakris, MD

A Deep Dive Into the Cardio-Renal-Metabolic Pathway


George L. Bakris, MD

Why Obesity Matters in Cardiology 2022


Karol E. Watson, MD, PhD, FACC

Pharmacological Weight Management for Heart Failure: It's a Cardiology Problem


Sheldon E. Litwin, MD, FACC

Can You Manage These Cardiometabolic Patients?


Robert H. Eckel, MD, FAHA, FACC

Educational Impact Challenge

The goal of this activity is for the learner to be better able to discuss strategies to reduce the risk of CV events.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print